CareFusion Acquires GE Healthcare’s Clinical Consumables Division
This article was originally published in The Gray Sheet
Following its acquisition of GE Healthcare’s Vital Signs unit for $500 million, CareFusion will become the second largest player in the more than $3 billion global respiratory and anesthesia consumables market.
You may also be interested in...
Device companies finished 2013 strong, raising $1.2 billion in Q4, the highest quarter total of the year. CVS Caremark’s $2.1 billion buy of Apria’s infusion therapy business was the largest M&A of the year, and late-stage venture rounds dominated the $423 million total in diagnostics funding.
GE Healthcare's $860 million acquisition of Vital Signs Inc. provides an entry into the rapidly growing sleep apnea market and complementary offerings for its anesthesia and broader respiratory care businesses
Advances in small activating RNAs, pioneered by MiNA Therapeutics, have caught the eye of Eli Lilly, and could be the next platform to exploit gene control mechanisms to produce a new therapeutic modality.